Learn about the Latest Therapy Approved by the FDA for Gastroesophageal Cancer Patients

A new type of therapy has been approved by the FDA for patients with Gastroesophageal Adenocarcinoma. Learn more.

On Monday, March 3, 2025, at 2 p.m., ECAN will host a free webinar to discuss Zolbetuximab (Vyloy) in depth. Dr. Samuel Klempner of Massachusetts General Hospital will explain which patients this new treatment may help, the risks and benefits of the new targeted therapy, and what the research tells us about its effectiveness. He will also answer your questions.

Register for the webinar at https://us02web.zoom.us/webinar/register/2317389532861/WN_iT07D9ebSXqLDe26I8-Z-A

Even if you cannot join us live, if you sign up we will send you a link to the recording afterward.

ECAN’s Webinar series is made possible by our generous sponsors